Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

被引：53

作者：

Nigro, Olga ^{[1
]}

Pinotti, Graziella ^{[1
]}

De Galitiis, Federica ^{[2
]}

Di Pietro, Francesca Romana ^{[2
,3
]}

Giusti, Raffaele ^{[3
]}

Filetti, Marco ^{[3
]}

Bersanelli, Melissa ^{[4
]}

Lazzarin, Alessandro ^{[4
]}

Bordi, Paola ^{[4
]}

Catino, Annamaria ^{[5
]}

Pizzutilo, Pamela ^{[5
]}

Galetta, Domenico ^{[5
]}

Marchetti, Paolo ^{[2
,6
]}

Botticelli, Andrea ^{[6
]}

Scagnoli, Simone ^{[6
]}

Russano, Marco ^{[7
]}

Santini, Daniele ^{[7
]}

Torniai, Mariangela ^{[8
]}

Berardi, Rossana ^{[8
]}

Ricciuti, Biagio ^{[9
]}

De Giglio, Andrea ^{[9
]}

Chiari, Rita ^{[10
]}

Russo, Alessandro ^{[11
]}

Adamo, Vincenzo ^{[11
]}

Tudini, Marianna ^{[12
]}

Silva, Rosa Rita ^{[12
]}

Bolzacchini, Elena ^{[13
]}

Giordano, Monica ^{[13
]}

Di Marino, Pietro ^{[14
]}

De Tursi, Michele ^{[15
]}

Rijavec, Erika ^{[16
]}

Ghidini, Michele ^{[16
]}

Vallini, Ilaria ^{[1
]}

Stucci, Luigia Stefania ^{[17
]}

Tucci, Marco ^{[17
,25
]}

Pala, Laura ^{[18
]}

Conforti, Fabio ^{[18
]}

Queirolo, Paola ^{[18
]}

Tanda, Enrica ^{[19
]}

Spagnolo, Francesco ^{[19
]}

Cecchi, Federica ^{[19
]}

Bracarda, Sergio ^{[20
]}

Macrini, Serena ^{[20
]}

Santoni, Matteo ^{[21
]}

Battelli, Nicola ^{[21
]}

Fargnoli, Maria Concetta ^{[22
,23
]}

Porzio, Giampiero ^{[22
,24
]}

Tuzi, Alessandro ^{[1
]}

Suter, Matteo Basilio ^{[1
]}

Ficorella, Corrado ^{[22
,24
]}

机构：

[1] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy

[2] IDI IRCCS, Oncol & Oncol Dermatol, Rome, Italy

[3] Azienda Osped Univ St Andrea, Med Oncol, Rome, Italy

[4] Azienda Osped Univ Parma, Med Oncol, Parma, Italy

[5] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Bari, Italy

[6] Univ Roma La Sapienza, Dipartimento Sci Med Chirurg & Med Traslaz, Rome, Italy

[7] Med Oncol, Campus Biomed, Rome, Italy

[8] Univ Politecn Marche, Clin Oncol, Azienda Osped Univ Osped Riuniti Umberto 1, GM Lancisi, Ancona, Italy

[9] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy

[10] Osped Riuniti Padova Sud Madre Teresa Di Calcutta, Med Oncol, Monselice, Italy

[11] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[12] ASUR Marche, Area Vasta 2, Med Oncol, Fabriano, Italy

[13] Osped St Anna, ASST Lariana, Med Oncol, Como, Italy

[14] SS Annunziata Hosp, Clin Oncol Unit, Chieti, Italy

[15] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[16] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Med Oncol Unit, Milan, Italy

[17] Univ Bari, Med Oncol Unit, Dept Biomed Sci & Human Oncol, Bari, Italy

[18] IRCCS, European Inst Oncol, Div Med Oncol Melanoma Sarcoma & Rare Tumors, IEO, Milan, Italy

[19] Osped Policlin San Martino, IRCCS, Genoa, Italy

[20] Santa Maria Hosp, Dept Med Oncol, Terni, Italy

[21] Macerata Hosp, Dept Oncol, Macerata, Italy

[22] St Salvatore Hosp, Dept Dermatol, Laquila, Italy

[23] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[24] St Salvatore Hosp, Med Oncol, Laquila, Italy

[25] Tumori Inst Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 134卷

关键词：

Immunotherapy; Immune checkpoint; Nivolumab; Pembrolizumab; Atezolizumab; Immune-related adverse events; ELDERLY-PATIENTS; CANCER;

D O I：

10.1016/j.ejca.2020.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICIs) are lacking. Methods: We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in patients with advanced cancer. IrAEs were categorized into 'early' (<= 12 months) and 'late' (>12 months). Results: From September 2013 to October 2019, 436 consecutive patients were evaluated. Two hundred twenty-three experienced any grade early-irAEs (51.1%), whereas 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, whereas 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced GIII/GIV irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95% confidence interval [CI]: 2.8-4.2), whereas the median time to onset of late-irAEs was 16.6 months (95% CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (hazard ratio [HR] = 0.63 [95% CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95% CI: 0.37-1.56], p = 0.452). In addition, the time-adjusted cumulative risk of death in accordance with both early-irAEs (HR = 0.79 [95% CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95% CI: 0.49-1.74], p = 0.811) did not show statistically significant differences. Conclusion: Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：19 / 28

页数：10

共 50 条

[1] Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study
Nigro, Olga
Pinotti, Graziella
Giusti, Raffaele
Filetti, Marco
De Galitiis, Federica
Di Pietro, Francesca Romana
Bersanelli, Melissa
Lazzarin, Alessandro
Catino, Annamaria
Pizzutillo, Pamela
Russano, Marco
Torniai, Mariangela
Ricciuti, Biagio
Russo, Alessandro
Tudini, Marianna
Bolzacchini, Elena
Di Marino, Pietro
Rijavec, Erika
Vallini, Ilaria
Ficorella, Corrado
Cortellini, Alessio
JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
[2] Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
Nigro, O.
Cortellini, A.
Giusti, R.
Marchetti, P.
De Galitiis, F.
Di Pietro, F. R.
Bersanelli, M.
Lazzarin, A.
Galetta, D.
Pizzutillo, P.
Santini, D.
Torniai, M.
De Giglio, A.
Russo, A.
Silva, R. R.
Bolzacchini, E.
Natoli, C.
Rijavec, E.
Vallini, I.
Pinotti, G.
ANNALS OF ONCOLOGY, 2019, 30
[3] Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment
Kim, Sarah
Colevas, A. Dimitrios
Tse, Stephanie
On, Sandy
Cheung, Edna
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital
Zheng, Jianping
Cui, Tongjian
Gao, Yu
Li, Ting
EUROPEAN JOURNAL OF INFLAMMATION, 2022, 20
[5] Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors
Xin, Zhaodan
You, Liting
Na, Feifei
Li, Jin
Chen, Min
Song, Jiajia
Bai, Ling
Chen, Jie
Zhou, Juan
Ying, Binwu
EUROPEAN JOURNAL OF CANCER, 2023, 184 : 124 - 136
[6] PD-1 immune checkpoint inhibitors and serious immune-related adverse events
Baek, Yeon-Hee
Kang, Eun Joo
Hong, Soojung
Park, So-Hee
Kim, Ju Hwan
Wong, Ian C.
Au, Philip C. -M.
Cheung, Ching-Lung
Shin, Ju-Young
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 293 - 293
[7] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Yanting
Li, Hongyan
FRONTIERS IN NEUROSCIENCE, 2023, 17
[8] Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Yoon, Jee Hee
Hong, A. Ram
Kim, Hee Kyung
Kang, Ho-Cheol
ENDOCRINOLOGY AND METABOLISM, 2021, 36 (02) : 413 - 423
[9] New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer
Hall, Kevin H.
Liu, Yuan
Jiang, Chen
Harvey, R. Donald
PHARMACOTHERAPY, 2020, 40 (02): : 133 - 141
[10] Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
Griewing, Luisa Maria
Schweizer, Claudia
Schubert, Philipp
Rutzner, Sandra
Eckstein, Markus
Frey, Benjamin
Haderlein, Marlen
Weissmann, Thomas
Semrau, Sabine
Gostian, Antoniu-Oreste
Mueller, Sarina K.
Traxdorf, Maximilian
Iro, Heinrich
Zhou, Jian-Guo
Gaipl, Udo S.
Fietkau, Rainer
Hecht, Markus
BMC CANCER, 2021, 21 (01)

← 1 2 3 4 5 →